- Home
- AVTX vs ARMP Comparison
AVTX vs ARMP Comparison
Compare AVTX & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVTX
- ARMP
- Stock Information
- Founded
- AVTX 2011
- ARMP N/A
- Country
- AVTX United States
- ARMP United States
- Employees
- AVTX N/A
- ARMP N/A
- Industry
- AVTX Biotechnology: Pharmaceutical Preparations
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AVTX Health Care
- ARMP Health Care
- Exchange
- AVTX Nasdaq
- ARMP Nasdaq
- Market Cap
- AVTX 57.4M
- ARMP 52.1M
- IPO Year
- AVTX 2015
- ARMP N/A
- Fundamental
- Price
- AVTX $4.96
- ARMP $2.17
- Analyst Decision
- AVTX Strong Buy
- ARMP Strong Buy
- Analyst Count
- AVTX 7
- ARMP 1
- Target Price
- AVTX $31.00
- ARMP $9.00
- AVG Volume (30 Days)
- AVTX 122.3K
- ARMP 22.0K
- Earning Date
- AVTX 08-11-2025
- ARMP 08-12-2025
- Dividend Yield
- AVTX N/A
- ARMP N/A
- EPS Growth
- AVTX N/A
- ARMP N/A
- EPS
- AVTX N/A
- ARMP N/A
- Revenue
- AVTX $441,000.00
- ARMP $4,699,000.00
- Revenue This Year
- AVTX N/A
- ARMP $8.43
- Revenue Next Year
- AVTX N/A
- ARMP N/A
- P/E Ratio
- AVTX N/A
- ARMP N/A
- Revenue Growth
- AVTX N/A
- ARMP 14.24
- 52 Week Low
- AVTX $3.39
- ARMP $0.90
- 52 Week High
- AVTX $16.00
- ARMP $3.42
- Technical
- Relative Strength Index (RSI)
- AVTX 57.49
- ARMP 62.41
- Support Level
- AVTX $4.76
- ARMP $1.85
- Resistance Level
- AVTX $5.05
- ARMP $2.00
- Average True Range (ATR)
- AVTX 0.30
- ARMP 0.16
- MACD
- AVTX 0.03
- ARMP 0.00
- Stochastic Oscillator
- AVTX 84.75
- ARMP 86.00
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.